Diagnos Laboratorium Utama Tbk. vs Sarimelati Kencana Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp224 (market cap 310.75B, 963.6K 24h volume), while Sarimelati Kencana Tbk. trades at Rp185 (market cap 553B, 3.72M 24h volume). The key difference: Sarimelati Kencana Tbk. is the larger of the two by market cap, and Sarimelati Kencana Tbk. is more actively traded (3.72M versus 963.6K). Which is the better fit depends on your goals.
| DGNS | PZZA | |
|---|---|---|
Market Cap | 310.75B | 553B |
Volume | 963.6K | 3.72M |
Lot | 9.64K | 37.22K |
Turnover | 217.67M | 666.16M |
Average Price | 225.89 | 179 |
Value | 217.67M | 666.16M |
Indicative Equilibrium Price | 226 | 185 |
Indicative Equilibrium Volume | 1K | 50 |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Sarimelati Kencana Tbk. (the Company) was established based on Notarial Deed No. 132 dated December 16, 1987 of Lieke Lianadevi Tukgali, S.H.
Read more on PZZA →